Nigerian Public Alert 62: The National Agency for Food and Drug Administration and Control (NAFDAC) is notifying healthcare professionals and the public of confirmed counterfeit batches of Avastin® 400mg/16ml (Bevacizumab) and Tecentriq® 1200mg/20ml (Atezolizumab) circulating in Nigeria. This alert is issued in response to official communications from Roche Nigeria, which have confirmed several cases of counterfeit products in Nigeria.
The Marketing Authorization Holder (MAH) reported receiving complaints from healthcare professionals across Nigeria. In many instances, patients brought counterfeit products to healthcare facilities. These counterfeit items were reportedly sold at significantly lower prices, ranging from NGN 180,000 to NGN 350,000.
On investigation, the MAH (Roche Nigeria) compared the complaint samples to the genuine retained samples. The findings have provided clear evidence of counterfeit packaging material of the reported products.
The following differences were observed during investigation
- Batch numbers do not correspond to genuine Roche batches.
- Differences in artwork and printing quality.
- Wrong placement of text.
- Incorrect variable data.
- Tamper-evident labels inconsistent with genuine Roche products.
- Serial numbers not corresponding to the genuine Roche serialisation system
Chemical analyses could not be conducted because the investigation depended on packaging photographs sent by the complainants; no physical samples were available for Roche to return.
AVASTIN (bevacizumab) is indicated for the treatment of recurrent glioblastoma in adults. It is a tumour-starving (anti-angiogenic) therapy.
TECENTRIQ (atezolizumab) is a prescription immunotherapy used to treat several advanced cancers, including non-small cell lung cancer (NSCLC), extensive-stage small cell lung cancer (ES-SCLC), hepatocellular carcinoma (liver cancer), and melanoma.
Risk Statement
Counterfeit oncology medicines may contain incorrect or no active ingredients, harmful contaminants, or incorrect dosage strength. This may result in treatment failure, disease progression, serious adverse events, or death
Product details
The details of the counterfeit products are as follows:
| Product Name | Stated Manufacturer on Counterfeit Pack | Batch Number | Manufacturing Date | Expiry Date |
| Avastin 400mg/16ml | Made for F. Hoffmann-La Roche Ltd, Basel, Switzerland, by Roche Diagnostics GmbH, Mannheim, Germany | H4239A70 | 03/2024 | 10/2026 |
| Avastin 400mg/16ml | Made for F. Hoffmann-La Roche Ltd, Basel, Switzerland, by Roche Diagnostics GmbH, Mannheim, Germany | H2290A34 | 08/2024 | 05/2027 |
| Avastin 400mg/16ml | Made for F. Hoffmann-La Roche Ltd, Basel, Switzerland, by Roche Diagnostics GmbH, Mannheim, Germany | A3508B02 | 07/2024 | 12/2026 |
| Tecentriq 1200mg/20ml | Production place : F. Hoffmann-La Roche Ltd, Kaiseraugst, Switzerland | B3071A12 | Not provided on pack | 01/10/2026 |
All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the counterfeit product within the zones and states.
Importers, distributors, retailers, healthcare professionals, and caregivers are hereby advised to exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale, and use of counterfeit products. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng, or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
PositiveNaija Nigerian Public Alert
The Nigerian Public Alert 62 initiative by PositiveNaija is aimed at keeping Nigerians well-informed particularly in regards to their safety and development. For future developments on this news, kindly follow up through the official communication channels of the reporting/regulatory authority.
We publish these alerts for free and will appreciate your support for our work – Moniepoint – 9064503292 – United Green Stars Worldwide Limited (kindly describe as “donation or gift”). Thank you.
